Armata Pharmaceuticals, Inc. (FRA:TG1N)

Germany flag Germany · Delayed Price · Currency is EUR
5.05
+0.59 (13.23%)
At close: Dec 4, 2025
155.05%
Market Cap 175.82M
Revenue (ttm) 4.31M
Net Income (ttm) -39.97M
Shares Out n/a
EPS (ttm) -1.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 75
Open 5.05
Previous Close 4.46
Day's Range 5.05 - 5.05
52-Week Range 0.70 - 6.25
Beta n/a
RSI 47.22
Earnings Date Mar 16, 2026

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing syn... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Deborah Birx
Employees 60
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol TG1N
Full Company Profile

Financial Performance

In 2024, Armata Pharmaceuticals's revenue was $5.17 million, an increase of 14.24% compared to the previous year's $4.53 million. Losses were -$18.92 million, -72.60% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.